Radiosensitization of human melanoma cells by sorafenib (BAY 43-9006), a multi-kinase inhibitor

被引：0
|
作者：
Munshi, Anupama [1 ]
Tanaka, Toshimitsu [1 ]
Hobbs, Marvette [1 ]
Meyn, Raymond E., Jr. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4671
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Randomized Phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)
    Escudier, B.
    Szczylik, C.
    Eisen, T.
    Oudard, S.
    Stadler, W. M.
    Schwartz, B.
    Shan, M.
    Bukowski, R. M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 226 - 226
  • [2] Randomised phase-III-study of the multi-kinase inhibitors Sorafenib (BAY 43-9006) for patients with advanced renal cell carcinoma
    Staehler, M.
    Siebels, M.
    Stief, C.
    Jaeger, E.
    Heinzer, H.
    Grimm, M. -O.
    Gschwend, J.
    Wirth, M.
    Michell, M. -S.
    Rohde, D.
    Krause, S.
    Siegsmund, M.
    Scheuring, U.
    Schwartz, B.
    Escudier, B.
    ONKOLOGE, 2007, 13 : 18 - 19
  • [3] Randomized discontinuation trial of sorafenib (BAY 43-9006)
    Jain, Lokesh
    Venitz, Juergen
    Figg, William D.
    CANCER BIOLOGY & THERAPY, 2006, 5 (10) : 1270 - 1272
  • [4] Sorafenib (BAY 43-9006): Review of Clinical Development
    Ng, Raymond
    Chen, Eric X.
    CURRENT CLINICAL PHARMACOLOGY, 2006, 1 (03): : 223 - 228
  • [5] Apoptosis induced by the multi-kinase inhibitor BAY 43-9006 in human leukemia cells involves downregulation of Mcl-1 through inhibition of translation.
    Rahmani, M
    Davis, EM
    Bauer, C
    Dent, P
    Grant, S
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9104S - 9104S
  • [6] Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006)
    Levy, Joan B.
    Pauloski, Nicole
    Braun, Deborah
    Derome, Mary
    Jordan, Jerold
    Shi, Hong
    Weaver, Daniel
    Chang, Yong
    Bortolon, Elizabeth
    Henderson, Arris
    Fracasso, Paul
    Burd, Amy
    Elting, James
    Lynch, Mark
    Reddy, Sanjeeva
    Wilhelm, Scott M.
    CANCER RESEARCH, 2006, 66 (08)
  • [7] Sorafenib (bay 43-9006) in patients with advanced renal cell cancer (MRCC) as second line therapy - Unicentric, results of an multicentric randomised phase III trial of the multi multi-kinase inhibitor
    Staehler, Michael D.
    Haseke, Nicolas
    Schoeppler, Gita M.
    Stadler, Thomas
    Graser, Anno
    Siebels, Michael
    Stief, Christian G.
    JOURNAL OF UROLOGY, 2007, 177 (04): : 166 - 167
  • [8] Alteration of the RAS/BRAF/MEK/MAPK pathway by BAY 43-9006 (sorafenib) in metastatic melanoma
    Pavlick, A.
    Liebes, L.
    Osman, I.
    Brooks, P.
    Yee, H.
    Polsky, D.
    Hamilton, A.
    Wright, J.
    Muggia, F.
    EJC SUPPLEMENTS, 2006, 4 (12): : 178 - 178
  • [9] Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: Mechanisms of hypertension.
    Veronese, ML
    Flaherty, KT
    Townsend, R
    Mosenkis, A
    Zimmer, R
    Rosen, M
    Gallagher, M
    O'Dwyer, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 135S - 135S
  • [10] Phase I trial of sorafenib (BAY 43-9006) combined with dacarbazine (DTIC) in patients with metastatic melanoma
    Eisen, T.
    Ahmad, T.
    Marais, R.
    Gibbens, I.
    James, M.
    Affolter, A.
    Chao, D.
    Bergamini, L.
    Schwartz, B.
    Gore, M. E.
    EJC SUPPLEMENTS, 2005, 3 (02): : 349 - 349
12345